Top

CNS Drugs

Published in:

01-04-2002 | Review Article

Advances in Atypical Antipsychotics for the Treatment of Schizophrenia

New Formulations and New Agents

Authors: Dr James P. Kelleher, Franca Centorrino, Matthew J. Albert, Ross J. Baldessarini

Published in: CNS Drugs | Issue 4/2002

Abstract

Innovation in atypical antipsychotic agents continues with new preparations of available drugs as well as novel agents. In this article, we provide an update on these novel products by reviewing information from a computerised literature search, recent abstracts and discussions with industry representatives.

A generic formulation of clozapine is now available. It may be less well absorbed and/or less effective than Clozaril®¹, although evidence is conflicting. A fatty acid amide derivative of clozapine is in early development.

A liquid formulation of risperidone is currently available, which may be a useful treatment for psychotic agitation as well as a preferable alternative to tablets for some patients. A depot formulation is in development for the long-term management of psychosis.

An orally disintegrating tablet formulation of olanzepine is a useful alternative to standard tablets. A short-acting injectable formulation of the drug is in development for psychotic agitation.

Sachets and slow-release formulations of quetiapine are in development. Ziprasidone, a recently launched agent, is available in tablet form for schizophrenia/schizoaffective disorder, psychotic depression and mania. A short-acting injectable formulation is in development for psychotic agitation.

Aripiprazole (tablets) and iloperidone (tablets and depot injection) are two antipsychotics in development for schizophrenia/schizoaffective disorder (available information regarding iloperidone is very limited).

These new formulations and agents should broaden options for the treatment of psychosis.

Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders: antipsychotic and antimanic agents. In: Hardman JG, Limbird LE, Gilman AG, editors. The pharmacologic basis of therapeutics. New York: McGraw-Hill Press, 2001

Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16(1): 23–15PubMedCrossRef

Weiss E, Hummer M, Koller D, et al. Off-label use of antipsychotic drugs. J Clin Psychopharmacol 2000; 20: 695–8PubMedCrossRef

Tohen M, Sanger TM, McElroy SL, et al. Olanzapine vs placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156: 702–9

Physicians’ desk reference. Montvale (NJ): Medical Economics Company, Inc., 2000

Meyer M. FDA requirements for approval of generic drug products. JCP CNS Capsules 2000; 2: 2–3

Lam YW, Ereshefsky L, Toney GB, et al. Branded vs generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001; 62Suppl. 5: 18–24PubMed

Burton TM. Doctors raise warnings about a form of clozapine. The Wall Street Journal 2000 Oct 24; Sect. B: 4

Barbey JT. Single-dose bioequivalence investigation comparing mylan clozapine tablets with Sandoz clozapine tablets. Washington, DC: Mylan Pharmaceuticals, 1999

10.

Communications/IVAX C: IVAX refutes Wall Street Journal article on clozapine. 2000 Oct 25

11.

Ereshefsky L, Lam YWF, Toney G, et al. Clozapine bioequivalence in patients [poster]. 3rd Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP); 2000; Washington, DC

12.

Toney G, Ereshefsky L, Lam YWF, et al. Interchangeability of clozapine formulations in stabilized patients [poster]. 3rd Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP); 2000; Washington, DC

13.

Ereshefsky L, Lam YWF, Toney G, et al. Switching clozapine formulations results in pharmacokinetic and pharmacodynamic differences [poster]. 3rd Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP); 2000; Washington, DC

14.

Kluznik JC. Clinical effects of a randomized switch from branded to generic clozapine. JCP CNS Capsules 2000; 2: 5–6

15.

Early J, Binz W, Teter C. Clozaril conversion to generic clozapine [poster]. 3rd Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP); 2000; Washington, DC

16.

Bellnier T, Singh RP, Karki S, et al. Evaluation of the interchangeability of generic clozapine with brand-name Clozaril [poster]. 11th Annual New York State Mental Health Research Conference; 1999; Albany

17.

Sajbel TA, Carter GW, Wiley RB. Converting patients from brand-name clozapine to generic clozapine. Ann Pharmacother 2001 Mar; 35(3): 281–4PubMedCrossRef

18.

Kumar V. Safety of clozapine (Zenith Goldline) in the management of geriatric patients. Int J Geriatr Psychopharmacol 1998; 1: 208–12

19.

Sheth N, Kumar V. Review of more than 21,000 patients exposed to ZGP clozapine over a 2-year period, Zenith Goldline, 2000

20.

Clozapine. US Food and Drug Administration Center for Drug Evaluation and Research [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/clozapine/clozapine.htm [Accessed 2001 Aug 2]

21.

Drug topics red book. Montvale (NJ): Medical Economics Company, Inc., 2001

22.

Baldessarini RJ, Campbell A, Webb NL, et al. Fatty acid derivatives of clozapine: prolonged antidopaminergic activity of docosahexaenoylclozapine in the rat. Neuropsychopharmacology 2001; 24: 55–65PubMedCrossRef

23.

Moller HJ, Gagiano CA, Addington DE, et al. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. Int Clin Psychopharmacol 1998; 13: 99–106PubMedCrossRef

24.

Janicak PG, Keck Jr PE, Davis JM, et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol 2001 Aug; 21(4): 360–8PubMedCrossRef

25.

Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998 May–Jun; 21(3): 176–80PubMed

26.

Currier GW, Simpson GM. Risperidone liquid concentrate vs intramuscular haloperidol for control of psychotic agitation [abstract]. 10th Biennial Workshop on Schizophrenia; 2000 Feb 5–11; Davos

27.

Ecrdekens M, Rasmussen M, Vermeulen A, et al. Kinetics and safety of a novel risperidone depot formulation [poster]. 40th Annual New Compounds and Drug Evaluation Unit (NCDEU) meeting; 2000 May 30–Jun 3; Boca Raton

28.

First atypical antipsychotic agent approved in the US for the long-term treatment of schizophrenia. Medical Education Network, Mediview FAX BLAST, 2000

29.

Chue P, Jones B, Taylor C. Dissolution profile and safety of olanzapine orally-disintegrating tablet in patients with schizophrenia [abstract]. Schizophr Res 2000; 41Suppl. 1: 192CrossRef

30.

Kinon BJ, Hill AL, Lin L. Zyprexa Zydis in the treatment of acutely ill, non-compliant schizophrenic patients [abstract]. Annual US Psychiatric and Mental Health Congress; 2000 Nov 16–19; San Diego

31.

Wright P, Birkett M, Ferchland I, et al. Intramuscular olanzapine: rapid, effective, sustained and safe alleviation of acute agitation in patients with schizophrenia [abstract]. Eur Neuropsychopharmacol 2000; 10Suppl. 3: S304CrossRef

32.

Wright P, Birkett M, Meehan K, et al. A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients [abstract]. Eur Neuropsychopharmacol 2000; 10Suppl. 3: S304CrossRef

33.

Reinstein M, Sonnenberg J, Chasanov M, et al. Comparative efficacy and tolerability of quetiapine at high and low doses [poster]. 155th Annual Meeting of the American Psychiatric Association; 2001 May 5–Jun 10; New Orleans

34.

Zorn S, Lebel LA, Schmidt AW, et al. Pharmacological and neurochemical studies with the new antipsychotic ziprasidone. In: Palomo T, Benninger R, Archer T, editors. Interactive monoaminergic disorders. Madrid: Editorial Sintesis, 1999: 377–93

35.

Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101–13PubMed

36.

37.

Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491–505

38.

Keck Jr PE, Ferguson J, Feighner J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140: 173–84CrossRef

39.

Goff DC, Posever T, Herz L, et al. An exploratory haloperidolcontrolled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18: 296–304PubMedCrossRef

40.

Keck Jr PE, Ince K, Mandel F. A 3-week, double-blind, randomized trial of ziprasidone in the acute treatment of mania [poster]. 52nd Institute on Psychiatric Services, American Psychiatric Association; 2000 Oct 25–29; Philadelphia

41.

Kim Y, Oksanen DA, Massefski Jr W, et al. Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether. J Pharm Sci 1998; 87: 1560–7PubMedCrossRef

42.

Swift RH, Harrigan EP, van Kammen DP. A comparison of fixed-dose intramuscular (IM) ziprasidone with flexible-dose IM haloperidol [abstract]. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30–Jun 4; Toronto

43.

Bender KJ. Antipsychotic evolution from A to Z: examining ziprasidone. Psychiatric Times Monograph, 1998 Dec: 7–10

44.

FDA Psychopharmacological Drugs Advisory Committee: Briefing document for Zeldox capsules [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf 2000 [Accessed 2001 Aug 1]

45.

Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight-gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96PubMed

46.

Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20: 612–27PubMedCrossRef

47.

Burris KD, Molski TF, Ryan E, et al. Aripiprazole is a high affinity partial agonist at human D2 dopamine receptors [abstract S129]. 22nd Annual Meeting of International Congress of Neuropsychopharmacology (CINP); 2000 Jul 9–13; Brussels

48.

Inoue T, Domae M, Yamada K, et al. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996; 277: 137–43PubMed

49.

Mallikaarjun S, Salazar DE, Bramer SL. The pharmacokinetics, tolerability and safety of aripiprazole following single and multiple oral dose administration [abstract S123]. 22nd Annual Meeting, International Congress of Neuropsychopharmacology (CINP); 2000 Jul 9–13; Brussels

50.

Daniel DG, Saha AG, Ingenito G, et al. Aripiprazole, a novel antipsychotic: overview of a phase II study result [abstract S157]. 22nd Annual Meeting, International Congress of Neuropsychopharmacology (CINP); 2000 Jul 9–13; Brussels

51.

Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo [abstract S124]. 22nd Annual Meeting, International Congress of Neuropsychopharmacology (CINP); 2000 Jul 9–13; Brussels

52.

Novartis. Titan and Novartis plan additional clinical trials to further strengthen profile of iloperidone for the treatment of schizophrenia [press release]. Available from URL: http://www.us.novartis.com/press_releases/releases/pr_rel_07232001.html [Accessed 2002 Mar 6]

53.

Lasser RA, Guven A, Hourani J, et al. A prospective study to evaluate the safety, tolerability, and efficacy of iloperidone compared with placebo in treating psychotic and behavioral symptoms in elderly patients with dementia [abstract]; 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23–26; San Francisco (CA)

54.

Clinical studies: iloperidone. Available from URL: http://www.titanpharm.com/Presentation/Iloperidone_slides_files/frame.htm [Accessed 2002 Mar 6]

55.

Tandon R, Jibson MD. Pharmacologic treatment of schizophrenia: what the future holds. CNS Spectrums 2001; 6: 980–6PubMed

56.

Corbett R, Griffiths L, Shipley JC. Iloperidone. Cent Nerv Syst Drug Rev 1997; 3: 120–47

57.

Jain KK. An assessment of iloperidone in the treatment of schizophrenia. Expert Opin Investig Drugs 2000; 9: 2935–43PubMedCrossRef

58.

Matkovits-Gupta T, Cucchiaro J, El-Bizri H, et al. Safety and efficacy of iloperidone in patients with psychotic disorders: a randomized, double-blind multicenter study [abstract]. Schizophr Res 2001; 49Suppl. 1–2: 238

59.

Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59: 294–9PubMedCrossRef

Title: Advances in Atypical Antipsychotics for the Treatment of Schizophrenia
New Formulations and New Agents
Authors: Dr James P. Kelleher
Franca Centorrino
Matthew J. Albert
Ross J. Baldessarini
Publication date: 01-04-2002
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 4/2002
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200216040-00004

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Advances in Atypical Antipsychotics for the Treatment of Schizophrenia

New Formulations and New Agents

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2002

Discontinuation Syndrome in Dysthymic Patients Treated with Selective Serotonin Reuptake Inhibitors

Optimal Timing of Thrombolytic Therapy in Acute Ischaemic Stroke

Pharmacological Treatment of Psychotic Agitation

Interactions Between Psychotropics, Anaesthetics and Electroconvulsive Therapy

Interactions Between Antiepileptic Drugs and Hormonal Contraception